株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ヒト成長ホルモンの世界市場:2018〜2022年

Global Human Growth Hormone Market 2018-2022

発行 TechNavio (Infiniti Research Ltd.) 商品コード 320559
出版日 ページ情報 英文 110 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.86円で換算しております。
Back to Top
ヒト成長ホルモンの世界市場:2018〜2022年 Global Human Growth Hormone Market 2018-2022
出版日: 2018年12月14日 ページ情報: 英文 110 Pages
概要

成長ホルモン欠乏による疾患の発症率、罹患率の上昇が世界のヒト成長ホルモン市場の拡大を推進しています。世界のヒト成長ホルモン市場は2022年までCAGR4%で拡大すると予測されています。

当レポートでは、世界のヒト成長ホルモン市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入するベンダーのプロファイルについてまとめています。

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 調査方法

第4章 市況

  • 市場エコシステム
  • 市場の特性
  • 市場セグメンテーション分析

第5章 パイプライン分析

第6章 市場規模

  • 市場の定義
  • 市場規模(2017年)
  • 市場規模と予測(2017〜2022年)

第7章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入者の脅威
  • 代用品の脅威
  • ライバルの脅威
  • 市場状況

第8章 薬剤別市場セグメンテーション

第9章 用途別市場セグメンテーション

  • セグメンテーション
  • 比較
  • 成長ホルモン欠乏
  • ISS
  • ターナー症候群
  • PWS
  • その他

第10章 競合環境

第11章 地域別動向

  • セグメンテーション
  • 比較
  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域
  • 市場の機会

第12章 意思決定の枠組み

第13章 促進因子と課題

第14章 市場動向

第15章 ベンダー環境

第16章 ベンダー分析

  • 網羅されるベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Pfizer

第17章 付録

図表
  • Exhibit 01: Parent market
  • Exhibit 02: Global human growth hormone market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pipeline drugs under Phase III stage of development 2017-2018
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2017
  • Exhibit 08: Validation techniques employed for market sizing 2017
  • Exhibit 09: Global - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 10: Global - Year-over-year growth 2018-2022 (%)
  • Exhibit 11: Five forces analysis 2017
  • Exhibit 12: Five forces analysis 2022
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2017
  • Exhibit 19: Application - Market share 2017-2022 (%)
  • Exhibit 20: Comparison by application
  • Exhibit 21: Growth hormone deficiency - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 22: Growth hormone deficiency - Year-over-year growth 2018-2022 (%)
  • Exhibit 23: ISS- Market size and forecast 2017-2022 ($ mn)
  • Exhibit 24: ISS - Year-over-year growth 2018-2022 (%)
  • Exhibit 25: Turner syndrome - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 26: Turner syndrome - Year-over-year growth 2018-2022 (%)
  • Exhibit 27: PWS - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 28: PWS - Year-over-year growth 2018-2022 (%)
  • Exhibit 29: Others - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 30: Others - Year-over-year growth 2018-2022 (%)
  • Exhibit 31: Market opportunity by application
  • Exhibit 32: Customer landscape
  • Exhibit 33: Global - Market share by geography 2017-2022 (%)
  • Exhibit 34: Regional comparison
  • Exhibit 35: Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 36: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 37: Top 3 countries in Americas
  • Exhibit 38: EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 39: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 40: Top 3 countries in EMEA
  • Exhibit 41: APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 42: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 43: Top 3 countries in APAC
  • Exhibit 44: Market opportunity
  • Exhibit 45: Vendor landscape
  • Exhibit 46: Landscape disruption
  • Exhibit 47: Vendors covered
  • Exhibit 48: Vendor classification
  • Exhibit 49: Market positioning of vendors
  • Exhibit 50: Eli Lilly - Overview
  • Exhibit 51: Eli Lilly - Business segments
  • Exhibit 52: Eli Lilly - Organizational developments
  • Exhibit 53: Eli Lilly - Geographic focus
  • Exhibit 54: Eli Lilly - Segment focus
  • Exhibit 55: Eli Lilly - Key offerings
  • Exhibit 56: Eli Lilly - Key customers
  • Exhibit 57: F. Hoffmann-La Roche - Overview
  • Exhibit 58: F. Hoffmann-La Roche - Business segments
  • Exhibit 59: F. Hoffmann-La Roche - Organizational developments
  • Exhibit 60: F. Hoffmann-La Roche - Geographic focus
  • Exhibit 61: F. Hoffmann-La Roche - Segment focus
  • Exhibit 62: F. Hoffmann-La Roche - Key offerings
  • Exhibit 63: F. Hoffmann-La Roche - Key customers
  • Exhibit 64: Novo Nordisk - Overview
  • Exhibit 65: Novo Nordisk- Business segments
  • Exhibit 66: Novo Nordisk - Organizational developments
  • Exhibit 67: Novo Nordisk - Geographic focus
  • Exhibit 68: Novo Nordisk - Segment focus
  • Exhibit 69: Novo Nordisk- Key offerings
  • Exhibit 70: Pfizer - Overview
  • Exhibit 71: Pfizer - Business segments
  • Exhibit 72: Pfizer - Organizational developments
  • Exhibit 73: Pfizer - Geographic focus
  • Exhibit 74: Pfizer - Segment focus
  • Exhibit 75: Pfizer - Key offerings
  • Exhibit 76: Pfizer - Key customers
目次
Product Code: IRTNTR23746

About this market

Increasing incidence and prevalence of growth hormone disorders due to the growth hormone deficiency is expected to drive the human growth hormone market over the forecast period. Moreover, various indications fall under the growth hormone disorders such as turner syndrome, growth hormone deficiency, acromegaly, Noonan syndrome, gigantism, and many more. Technavio's analysts have predicted that the human growth hormone market will register a CAGR of almost 4% by 2022.

Market Overview

Strong pipeline of human growth hormone

Many leading companies such as Novo Nordisk, Merck, and Pfizer have a strong pipeline in their portfolio for treating various growth hormone disorders. All these factors are expected to drive the global human growth hormone market during the forecast period.

Poor patient adherence

The poor patient adherence for human growth hormone due to uneasiness with growth hormone administration will impact the treatment adherence and results.

For the detailed list of factors that will drive and challenge the growth of the human growth hormone market during the 2018-2022, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Novo Nordisk and Pfizer the competitive environment is quite intense. Factors such as the strong pipeline of human growth hormone and the increasing incidence and prevalence of growth hormone disorders, will provide considerable growth opportunities to human growth hormone manufactures. Eli Lilly, F. Hoffmann-La Roche, Novo Nordisk, and Pfizer are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

  • Human growth hormone pipeline analysis

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY DRUG TYPE

  • Segmentation by drug type

PART 09: MARKET SEGMENTATION BY APPLICATION

  • Segmentation by application
  • Comparison by application
  • Growth hormone deficiency - Market size and forecast 2017-2022
  • ISS - Market size and forecast 2017-2022
  • Turner syndrome - Market size and forecast 2017-2022
  • PWS - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Market opportunity by application

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 14: MARKET TRENDS

  • Increasing incidence of growth disorders
  • No impact of biosimilar entry into market
  • Advanced technologies

PART 15: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 16: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Pfizer

PART 17: APPENDIX

  • List of abbreviations
Back to Top